Multiple sclerosis impairment scale and brain MRI in secondary progressive multiple sclerosis

Asta Theodorsdottir*, Pia Veldt Larsen, Helle Hvilsted Nielsen, Zsolt Illes, Mads Henrik Ravnborg


Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

12 Downloads (Pure)


Objective: To examine the Multiple Sclerosis Impairment Scale (MSIS) in secondary progressive MS (SPMS) in relation to the Expanded Disability Status Scale (EDSS), magnetic resonance imaging (MRI) outcomes, and mobility. Methods: In this observational single-center study, 68 secondary progressive multiple sclerosis (SPMS) patients were examined by MSIS, EDSS, functional mobility tests of upper/lower extremities, and multimodal MRI. Participants had EDSS ≥3.5, a decline in daily activities over the last year unrelated to relapses, and/or 6-month confirmed disability progression. Results: Mean disease duration was 23.1 ± 8.3 years and mean age 54.4 ± 8.1 years. MSIS, EDSS, and their corresponding motor, cerebellar, and sensory subscores correlated (p <.0001). Motor subscores of MSIS correlated stronger with Timed-25-Foot-Walk (T25FW) than pyramidal functional system score (FSS) (p =.03), but EDSS had a stronger correlation to T25FW than the total MSIS score (p =.01). MSIS cerebellar subscore correlated stronger with 9-Hole Peg Test (9-HPT) than cerebellar FSS (p =.04). The sensory MSIS subscore also showed correlation with 9-HPT in contrast to sensory FSS (p =.006). MSIS subscores had stronger correlations with MRI volumetry measures than FSS scores (lesion volume and putamen, thalamus, corpus callosum volumetry, p =.0001–0.0017). Conclusion: In patients with SPMS, MSIS correlated with functional motor tests. MSIS showed stronger correlations with atrophy of central nervous system areas, and may be more sensitive to scale cerebellar and sensory function than EDSS.

TidsskriftActa Neurologica Scandinavica
Udgave nummer3
Sider (fra-til)332-347
StatusUdgivet - mar. 2022

Bibliografisk note

Funding Information:
AT has served on a scientific advisory board for Roche, has received research grant from Novartis Healthcare, and support for congress participation from Roche, Biogen, Novartis Healthcare, Merck, and Sanofi Genzyme. PVL and MHR have nothing to disclose. HHN has received financial compensation for travels and consultations from Novartis Healthcare, Biogen, Teva, Sanofi‐Genzyme, and Roche, has received a research grant from the Danish MS society, and served as a board member on the MS Society Research Council. ZI has received speakers’ honoraria and/or research grants from Biogen, Roche, Sanofi, Novartis, Merck, Lundbeckfonden, and Scleroseforeningen, has been member of advisory boards at Alexion, Biogen, Sanofi, Merck, Roche, and Novartis, was member of the adjudication relapse committee in the SAKuraStar and SakuraSky trials, and has been principal investigator in studies sponsored by Biogen, Merck, and Sanofi.


Dyk ned i forskningsemnerne om 'Multiple sclerosis impairment scale and brain MRI in secondary progressive multiple sclerosis'. Sammen danner de et unikt fingeraftryk.